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Effects of warm ischemia 
and reperfusion on the liver 
microcirculatory phenotype of 
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Warm ischemia and reperfusion (WIR) causes hepatic damage and may lead to liver failure, however 
the mechanisms involved are largely unknown. Here we have characterized the microcirculatory status 
and endothelial phenotype of livers undergoing WIR, and evaluated the use of simvastatin in WIR injury 
prevention. Male Wistar rats received simvastatin, or vehicle, 30 min before undergoing 60 min of partial 
warm ischemia (70%) followed by 2 h or 24 h of reperfusion. Hepatic and systemic hemodynamics, 
liver injury (AST, ALT, LDH), endothelial function (vasodilatation in response to acetylcholine), KLF2 
and nitric oxide pathways, oxidative stress, inflammation (neutrophil and macrophage infiltration) 
and cell death were evaluated. Profound microcirculatory dysfunction occurred rapidly following WIR. 
This was evidenced by down-regulation of the KLF2 vasoprotective pathway, impaired vasodilatory 
capability and endothelial activation, altogether leading to increased hepatic vascular resistance and 
liver inflammation, with significant leukocyte infiltration, oxidative stress and cell death. Simvastatin 
preserved the hepatic endothelial phenotype, and blunted the detrimental effects of WIR on liver 
hemodynamics and organ integrity. In conclusion, WIR-induced injury to liver sinusoidal endothelial 
cells is mitigated by pre-treatment with Simvastatin probably through a KLF2-dependent mechanism.
Ischemia/reperfusion injury is the phenomenon of interruption of blood supply followed by restoration of blood 
flow and the accompanying oxygen, nutrient supply and shear stress. Clinically, warm ischemia/reperfusion 
(WIR) injury is almost unavoidable in liver resection surgery, liver transplantation, and in blood transfusion for 
hemorrhagic shock, and may lead to delayed graft function and liver failure. Two different phases can be distin-
guished during reperfusion: an early phase (within 2 h after restoring reperfusion), which is characterized by the 
release of reactive oxygen species (ROS) and production of inflammatory mediators (TNFα , chemokines)1,2, and 
a late phase (6–48 h after reperfusion), in which inflammatory responses caused by neutrophil and macrophage 
infiltration exacerbate the liver damage3. As demonstrated recently by our group, the effects of ischemia reper-
fusion are already significant under cold ischemia when further deterioration of hepatic microcirculation and 
endothelial dysfunction is seen4.
Kruppel-like factor 2 (KLF2) is a transcription factor predominantly expressed by the endothelial cell5 that 
induces expression of vasodilator, anti-thrombotic and anti-inflammatory genes (e.g. endothelial nitric oxide 
synthase (eNOS) and thrombomodulin)6,7 and inhibits the expression of adhesion molecules (vascular cell adhe-
sion molecule 1 (VCAM-1) and E-selectin)6,8 maintaining a vasoprotective endothelial phenotype. Experimental 
studies using endothelial cells have demonstrated that KLF2 expression is induced by physiological blood 
flow-derived shear stress9,10.
Statins are HMG-CoA inhibitors originally designed to lower cholesterol levels, however they have shown 
other therapeutic effects independent on lipid lowering11. Administration of simvastatin in experimental models 
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of chronic and acute liver injury has demonstrated its effectiveness in protecting the liver sinusoidal endothe-
lium12,13,4, nevertheless its potential applicability in situations of hepatic WIR is unknown. These beneficial effects 
of statins are due in part to the activation of KLF2 pathway that contributes in maintaining/restoring a healthy 
endothelial phenotype14,15.
In the present study we have characterized for the first time the hepatic microcirculatory status and sinusoidal 
endothelial phenotype of livers undergoing warm ischemia and reperfusion injuries, and evaluated the applica-
bility of simvastatin to improve or prevent warm ischemia/reperfusion injury.
Results
WIR causes microcirculatory derangements and endothelial dysfunction. Livers undergoing 
warm ischemia and reperfusion (WIR) exhibited significantly impaired microcirculation evidenced by a marked 
increase in intrahepatic vascular resistance at 2 h and 24 h of reperfusion, associated with increased portal pres-
sure and a reduction of portal blood inflow (Fig. 1a). Furthermore, WIR promoted the development of acute 
endothelial dysfunction defined as a reduced response to the endothelial-dependent vasodilator acetylcholine 
(Fig. 1b) and an increase in the sinusoidal expression of the liver sinusoidal endothelial cells (LSEC) capillariza-
tion marker von Willebrand Factor (vWF, Fig. 1b). The detrimental effects of WIR on liver endothelial function 
observed at 2 h of reperfusion were exacerbated after 24 h (Fig. 1b).
In addition, WIR caused a significant increase in the release of transaminases and LDH compared to sham 
operated animals especially at the early phase of reperfusion (Fig. 1c). At 24 h of reperfusion these parameters 
were decreased but still were significantly higher than in sham animals.
WIR reduces KLF2 expression and NO bioavailability. WIR caused a reduction in KLF2 liver pro-
tein expression at the early and late phases of reperfusion (Fig. 2a left), which was accompanied by a decrease 
in phosphorylated eNOS (Fig. 2a right) and a diminution in NO bioavailability (Fig. 2b). O2− production and 
nitrotyrosine formation (caused by the scavenging of NO by O2−) were significantly increased at both time points 
of reperfusion (Fig. 2c).
WIR promotes hepatic inflammation and cell death. WIR injury induced a rapid activation of the 
hepatic endothelium, as demonstrated by the increases in P-Selectin (5.8 fold and 2.3 fold increments at 2 h and 
24 h, respectively, p < 0.05) and VCAM-1 (Fig. 3), which was associated with subsequent infiltration and accu-
mulation of macrophages and, especially, neutrophils within the liver parenchyma (Fig. 3). In addition, terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining revealed that there was a significant 
15-fold increase in cell death after 2 h of reperfusion, which was partly resolved at 24 h but remaining significantly 
higher than in sham operated animals (Fig. 3).
Simvastatin improves WIR-mediated liver microcirculatory dysfunction. Simvastatin adminis-
tration 30 minutes before ischemia prevented the WIR-derived increment in intrahepatic vascular resistance, 
thus improving liver perfusion without changes in portal pressure (Fig. 4a). In addition, simvastatin significantly 
attenuated the development of acute endothelial dysfunction both at 2 and 24 h of reperfusion as evidenced by 
improved vasodilation in response to Ach (Fig. 4b top) and reduced sinusoidal vWF expression (Fig. 4b bottom). 
The improvement in hepatic hemodynamics was associated with a much less marked increase in transaminases 
and lactate dehidrogenase (LDH) release (Fig. 4c).
Simvastatin prevents KLF2 down-regulation and maintains NO bioavailability. Administration 
of simvastatin prior to ischemia maintained liver KLF2 protein expression and eNOS phosphorylation levels, 
which was especially evident at 2 h of reperfusion (Fig. 5a). This was accompanied by higher NO bioavailability 
(Fig. 5b), and by decreased O2− production and O2−-mediated NO scavenging (Fig. 5c).
Simvastatin administration inhibits endothelial activation, inflammation and cell death. Liver 
endothelial phenotype maintenance due to simvastatin administration prevented an increased expression in 
adhesion molecules (P-Selectin 55% lower at 2 h of reperfusion, and 98% at 24 h vs. vehicle-treated rats, p < 0.05; 
VCAM-1 Fig. 6), and neutrophil and macrophage infiltration (Fig. 6), both at the early and late phases of reperfu-
sion. Moreover, simvastatin-treated animals showed a significant reduction in hepatic cells death (Fig. 6).
Simvastatin increases KLF2 and improves the phenotype of hepatic cells in vitro. Simvastatin 
increased KLF2 mRNA expression not only in LSEC but also in primary hepatocytes and Kupffer cells 
(Supplementary Fig. S1a). This correlated with a slight improvement in the hepatocyte phenotype observed by 
a trend to an increase in the transcription factor HNF4α and a reduction in the Mrp3 transporter expression 
(Supplementary Fig. S1b). Regarding Kupffer cells, simvastatin treatment induced a polarization towards an 
anti-inflammatory M2 phenotype, evidenced by significant increases in the expression of Arg-1 and IL-10, with-
out significant changes in the markers of M1 phenotype TNF-α and iNOS (Supplementary Fig. S1c).
LSEC treated with simvastatin showed a statistically significant 8-fold and 2.6-fold increase in KLF2 and eNOS 
mRNA expression respectively after reperfusion. This was associated with a decrease in the mRNA expression of 
the pro-inflammatory & capillarization markers iNOS (1.00 ± 0.16 vs. 0.76 ± 0.19) and VCAM-1 1.00 ± 0.06 vs. 
0.85 ± 0.14). Furthermore, LSEC pre-treated with simvastatin exhibited lower levels of oxidative stress, measured 
as O2−, compared with vehicle-treated cells (1.00 ± 0.18 vs. 0.72 ± 0.18; p = 0.1).
Discussion
Liver sinusoidal endothelial cells (LSEC) damage following ischemia reperfusion (IR) injury is the first event in 
the development of graft failure. Although this was already suggested in the late 1980 s16, most research to date 
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has focused on other liver cell types. It is accepted that after IR there is an increase in LSEC ROS, together with an 
imbalance between decreased NO bioavailability (due to reduced production by eNOS and increased scavenging 
Figure 1. Liver warm ischemia and reperfusion leads to acute hepatic microvascular dysfunction.  
(a) Intrahepatic vascular resistance (IVR), portal pressure (PP) and portal blood flow (PBF) determined in 
rats that underwent 70% hepatic warm ischemia followed by 2 h or 24 h of reperfusion (WIR). (b) Hepatic 
endothelial function evaluation analyzing relaxation response to incremental doses of Ach (top) and vWF 
protein expression (down) in rats described in A. Representative images (40 × magnification). (c) Hepatic 
injury evaluated as release of transaminases (ALT, AST) and LDH in liver perfusate from rats described in A. 
(n = 8 per group; *p < 0.05 vs. sham).
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by ROS) and increased endothelin and thromboxane A2 levels, altogether promoting the expression of adhesion 
molecules, neutrophil adhesion and platelet aggregation17–19. However elucidation of the underlying mechanisms 
Figure 2. Hepatic warm ischemia and reperfusion induces a rapid down-regulation in KLF2 and its 
derived vasoprotective programs. (a) Representative images of hepatic KLF2, phosphorylated eNOS (p-eNOS) 
and total eNOS immunoblots and densitometric analysis normalized to β -actin from rats undergoing 1 h of 
partial ischemia followed by 2 h or 24 h of reperfusion (WIR), compared to the sham group. (b) cGMP levels in 
livers described in A. (c) Representative images and quantitative analysis of DHE staining and nitrotyrosinated 
proteins fluorohistochemistry (20 × magnification) (n = 8 per group; *p < 0.05 vs. sham). The red dotted line 
represents the sham group.
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Figure 3. Liver warm ischemia and reperfusion promotes endothelial cell activation, leukocyte infiltration 
and cell death. (a) Representative images of VCAM-1 and CD68 immunohistochemistry, neutrophil infiltration 
and TUNEL staining determined in livers from rats that underwent 1 h of partial hepatic ischemia followed by 
2 h or 24 h of reperfusion (WIR) (neutrophil magnification 40× , other 20× ); (b) quantitative analysis of at least 
8 fields/sample referred to its sham group (red dotted line). (n = 8 per group, *p < 0.05 vs. sham).
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of LSEC damage during hepatic IR injury, and its impact on the global reduction in organ viability and function 
after liver resection or transplantation is scarce. In this work we have characterized the hepatic microcirculation 
in a well-established model of warm ischemia and reperfusion of the liver, focusing predominantly on changes in 
LSEC phenotype, its mechanisms, consequences and prevention.
In the present study, we demonstrate for the first time that a short period of warm ischemia is enough to 
cause striking deleterious effects on the hepatic microcirculation markedly increasing the intrahepatic vascular 
Figure 4. Simvastatin prevents liver vascular dysfunction produced by warm ischemia and reperfusion injury. 
(a) Intrahepatic vascular resistance (IVR), portal pressure (PP) and portal blood flow (PBF) in rats pre-treated with 
vehicle or simvastatin and afterwards undergoing liver warm ischemia and reperfusion. (b) Endothelial function 
evaluation (top) and vWF immunohistochemistry (down) in animals described in A (40 × magnification), 
normalized to its corresponding vehicle-treated group (red dotted line). (c) Hepatic injury evaluation. (n = 8 per 
group; *p < 0.05 vs. vehicle).
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resistance (IVR), both at the early and late phases of reperfusion, leading to increased portal pressure and to a sig-
nificant reduction in hepatic perfusion. Furthermore, animals suffering WIR develop acute endothelial dysfunc-
tion evidenced by a decreased response to the endothelial dependent vasodilator acetylcholine20 and by increased 
Figure 5. Simvastatin pre-treatment maintains the KLF2-derived vasoprotection during warm ischemia 
and reperfusion injury. (a) Representative images of hepatic KLF2, p-eNOS and eNOS immunoblots 
and densitometric analysis normalized to β -actin. (b) Hepatic cGMP levels. (c) Representative images 
and quantitative analysis of DHE staining and nitrotyrosinated proteins fluorohistochemistry (20× ). All 
quantifications normalized to its corresponding vehicle (red dotted line). (n = 8 per group; *p < 0.05 vs. vehicle).
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expression of vWF21,22. In addition WIR caused liver damage, measured as increments in AST, ALT and LDH, as 
described previously23,24, especially at 2 h of reperfusion. At the late phase of reperfusion, levels of transaminases 
and LDH seem to improve most likely due to an initial resolution of liver injury; nevertheless they remain signif-
icantly higher than in sham-operated animals.
It has been described that blood flow-derived shear stress maintains a vasoprotective endothelial phenotype 
owing to the activation of the transcription factor KLF2, which mediates the transcription of several protective 
Figure 6. Simvastatin reduces hepatic endothelial activation, leukocyte infiltration and cell death 
derived from warm ischemia and reperfusion injury. Representative images of VCAM-1, neutrophil and 
macrophage infiltration, and cell death detection in livers from rats pre-treated with simvastatin, or its vehicle, 
before undergoing 1 h of warm ischemia followed by 2 h or 24 h of reperfusion (a) and its corresponding 
quantifications (b). Neutrophil 40× , other 20× , values normalized to its vehicle group (red dotted line). (n = 8 
per group, *p < 0.05 vs. vehicle).
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genes8,9,25. Indeed, recent studies have demonstrated that lack of the biomechanical stimulus determined by shear 
stress deteriorates the endothelial phenotype by down-regulating the expression of KLF24,10. Thus, we hypoth-
esized that during WIR blood inflow blockade may also decrease liver endothelial KLF2 expression, and this 
reduction will cause a loss of liver vasoprotection during reperfusion.
To evaluate our hypothesis we measured KLF2 protein expression in liver tissue observing a significant reduction 
after WIR, both at the early and the late phases of reperfusion. Interestingly, this decrease was accompanied by a 
reduction in eNOS activation, one of KLF2 target genes. We further evaluated the bioavailability of the vasodila-
tor NO by measuring the levels of cyclic guanosine monophosphate (cGMP) as a second messenger of NO and 
found a significant reduction in cGMP levels at the early phase of reperfusion. The reduction in NO bioavailability is 
explained by a combination of two factors: less synthesis due to reduced eNOS activity and; increased NO-scavenging 
by the high amount of O2− produced during reperfusion. This scavenging causes the formation of the free radical per-
oxynitrite that may rapidly react with cell components such as proteins, lipids, and DNA further damaging the cell26.
We further characterized the consequences of liver endothelial de-regulation during WIR by analyzing liver 
inflammation at two reperfusion time-points: early (2 h) and late (24 h). We evaluated hepatic VCAM-1 and 
P-selectin protein expression due to their implication in neutrophil adhesion and extravasation27–29 and found 
an up-regulation at early and late reperfusion periods. Indeed, neutrophil infiltration was slightly increased after 
2 h of reperfusion and greatly increased at 24 h. Furthermore macrophage activation and infiltration was also 
significantly increased at both reperfusion times. As it has been described, leukocytes produce pro-inflammatory 
cytokines and ROS further contributing to tissue damage30,31, this can also be observed in our results, with a vast 
O2− production at the late reperfusion phase. Microvascular dysfunction and parenchymal damage associated 
with WIR induced hepatic cell death.
Statins or HMG-CoA inhibitors were primarily designed to decrease cholesterol levels but they have also 
shown to have beneficial cholesterol-independent effects such as up-regulating KLF2-derived transcriptional 
programs that improve endothelial function14,32. Considering the detrimental effects of WIR on liver microcir-
culation, KLF2 vasoprotective cascades, and recent data from our group demonstrating the beneficial effects of 
simvastatin in the cirrhotic liver33, we have applied an acute pharmacological pre-treatment with simvastatin 
to preserve liver endothelial function during WIR. Some previous experimental studies have applied statins to 
WIR and have shown benefits in terms of organ injury and inflammation34–38, however they have not evaluated 
the effects of statins on liver microvascular function and phenotype, especially when administered shortly before 
ischemia, thus discarding possible concomitant effects of lipid-lowering.
Our results demonstrate that simvastatin administration 30 min before ischemia prevents the increase in 
hepatic vascular resistance during reperfusion, and that is associated with better liver perfusion at early and late 
reperfusion periods. Simvastatin pre-treatment also improved liver endothelial function and prevented the peak 
in transaminases and LDH release observed at 2 h of reperfusion.
Evaluation of the KLF2 pathway revealed that simvastatin is able to prevent liver KLF2 protein expression 
decay observed at the early reperfusion period, thus maintaining the activation of its target gene eNOS, enhancing 
NO bioavailability. Moreover, simvastatin-treated animals showed reduced levels of ROS. This might be explained 
by the antioxidant properties of KLF2 through activation of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and 
up-regulation of heme oxygenase 1 (HO-1)39,33. Finally, we found that simvastatin prevented the expression of 
adhesion molecules such as VCAM-1 and P-selectin on the endothelial surface reducing leukocyte infiltration, 
which may also be attributed to the anti-inflammatory properties of KLF26,40.
The results obtained in vivo were validated in vitro. LSEC cultured in an anoxia/reoxygenation system showed 
that simvastatin was able to partly abrogate the burst in oxidative stress and inflammation due to I/R, most prob-
ably due to the induction of the KLF2 protective pathway10. Furthermore, we herein demonstrate for the first 
time that simvastatin also activates the KLF2 pathway in other hepatic cells (ie. Hepatocytes and Kupffer cells), in 
which it also confers a protective phenotype. These observations complement previous data demonstrating the 
beneficial effects of statins in another non-parenchymal cell type, the hepatic stellate cells33, altogether reinforcing 
the concept of global hepatic protection in response to statins.
Despite the positive results achieved in this study using simvastatin in the setting of WIR injury, we have to 
acknowledge some limitations. First, the model of partial ischemia without hepatic resection, although repre-
sentative of the WIR that occurs in vivo after episodes of shock and/or hypovolemia, does not allow extrapolating 
what happens in liver resection surgery. On the other hand, the role of KLF2 in protection against liver WIR could 
be further delineated using genetic models where KLF2 expression would be knocked-down specifically.
In summary, the results herein reported shed light on the pathophysiology of liver ischemia reperfusion injury 
demonstrating that a warm ischemia period, even of short duration, profoundly affects the liver endothelial phe-
notype, which becomes dysfunctional, leading to an immediate increase in the hepatic vascular tone, inflamma-
tion, polymorphonuclear cells infiltration, and hepatic cell death. WIR-derived damage to the hepatic endothelium 
may be, at least in part, due to KLF2 down-regulation. Indeed, simvastatin pre-treatment maintains KLF2 vaso-
protective pathways and efficiently protects the hepatic microcirculation from WIR and prevents subsequent liver 
injury. Our data strongly suggest that simvastatin administration may represent an effective and simple approach 
to prevent or reduce liver damage in clinical situations associated with warm ischemia-reperfusion liver injury.
Methods
Animals and treatment. Male Wistar rats from Charles River Laboratories (Barcelona, Spain) weighting 
300–350 g were used. Rats were treated with simvastatin (1 mg/kg i.v., Calbiochem, San Diego, CA) or its vehicle 
(DMSO 0.1%) 30 minutes before ischemia. Animals were kept in environmentally controlled animal facilities at 
the Institut d’Investigacions Biomediques August Pi i Sunyer (IDIBAPS). All experiments were approved by the 
Laboratory Animal Care and Use Committee of the University of Barcelona and were conducted in accordance 
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with European Community guidelines for the protection of animals used for experimental or other scientific 
purposes (EEC Directive 86/609).
Liver Vascular Studies. Under anesthesia with intraperitoneal ketamine (100 mg/Kg, Merial Laboratories, 
Barcelona, Spain) and midazolam (5 mg/Kg, Normon, Tres Cantos, Madrid, Spain) partial warm ischemia affect-
ing 70% of liver volume was induced by clamping the portal triad irrigating the medial and left lateral lobes with 
an atraumatic clamp for 1 h41, which was followed by 2 h (short-term) or 24 h (long-term) of reperfusion. Sham 
operated animals were included. After the WIR period, hemodynamic studies were performed as previously 
described42. Briefly, a tracheotomy was performed and a polyethylene PE-240 tubing was inserted into the trachea 
to ensure a patent airway. PE-50 catheters were introduced into the femoral artery, for arterial pressure recording 
(mm Hg), and into the portal vein through the ileocolic vein, to measure portal pressure (mmHg). Then, the 
portal vein was carefully dissected free from connective tissue, and a non-constrictive perivascular transit-time 
ultrasonic flow probe (Transonic Systems, Ithaca, New York, USA) was placed around the vessel. The flow probe 
was connected to a flow-meter, to measure the portal vein blood flow (mL/min). Intrahepatic vascular resist-
ance (IVR; mmHg/mL·g·min−1) was calculated as: portal pressure/(portal vein blood flow/liver weight). Blood 
pressures and flows were registered on a multichannel computer-based recorder (PowerLab; ADInstruments, 
Colorado Springs, Colorado, USA). The external zero reference point was placed at the midportion of the animal. 
Hemodynamic data were collected after a 20-min stabilization period.
Immediately after the in vivo hemodynamic study, liver vascular responses were assessed in the isolated, 
in situ liver perfusion system, as described42. Livers were perfused at a constant portal flow of 35 mL/min and after 
20 minutes of stabilization, liver endothelial function was evaluated analyzing endothelium-dependent vasorelaxa-
tion to incremental doses of acetylcholine (Ach; 10−7 to 10−5 M) after pre-constriction with methoxamine (10−4 M).
Aliquots of the perfusate were sampled for the measurement of transaminases and lactate dehydrogenase 
(LDH) using standard methods at the Hospital Clinic of Barcelona’s CORE laboratory. At the end of the study, 
liver samples from lobules that suffered WIR were stored for molecular analysis as described below.
Liver cells isolation and treatments. Hepatocytes, Kupffer cells and liver sinusoidal endothelial cells 
(LSEC) were isolated from control rat livers by collagenase digestion followed by percoll gradient43.
Hepatocytes and Kupffer cells were treated with simvastatin (5 μ M) or its vehicle for 24 h. LSEC were treated 
with simvastatin (1 μ M) or its vehicle 1 h before undergoing 1 h anoxia using a BD GaspakTM System followed by 
24 h reoxygenation.
Von Willebrand Factor and P-Selectin immunohistochemistry. Liver samples were fixed in 10% for-
malin, embedded in paraffin and sectioned. After antigen retrieval procedure and endogenous peroxidase activ-
ity inhibition, sections were incubated with anti-von Willebrand Factor (1:400; Dako, Glostrup, Denmark) or 
anti-P-selectin (1:400; Biovision, Milpitas, CA) 1 h at room temperature. HRP-Rabbit/Mouse (Dako) secondary 
antibody was added. Colour development was induced by incubation with a DAB kit (Dako) and the sections were 
counterstained with hematoxylin. Sections were dehydrated and mounted. The specific staining was visualized and 
images were acquired using a microscope equipped with a digital camera and the assistance of Axiovision software. 
vWF relative volume was determined by point-counting morphometry on immunoperoxidase-stained sections, 
using a point grid to obtain the number of intercepts over vWF positive cells over the tissue. Six fields were counted 
in each liver. All measurements were performed by two independent blinded observers. The relative volume was cal-
culated by dividing the number of points positive in sinusoidal areas by the total number of points over liver tissue.
Western Blotting. Liver samples were processed and western blot performed as described42. Used pri-
mary antibodies: KLF2 (Santa Cruz Biotech, Santa Cruz, CA), phosphorylated eNOS at Ser1177 (Cell Signaling, 
Danvers, MA), and total eNOS (BD Transduction Laboratories, Lexington, KY), all 1:1000. Blots were revealed 
by chemiluminescence and protein expression was determined by densitometric analysis using the Science Lab 
2001, Image Gauge (Fuji Photo Film, Düsseldorf, Germany). Blots were also assayed for β -actin (Sigma-Aldrich) 
content as standardization of sample loading.
Superoxide and nitric oxide bioavailability. In situ O2− levels were assessed in LSEC and liver tis-
sue with the oxidative fluorescent dye dihydroethidium (DHE 10 μ M; Molecular Probes Inc., Eugene, OR) as 
described44,33. Fluorescence images were obtained with a fluorescence microscope (Olympus BX51, Tokyo, 
Japan), and quantitative analysis of at least eight images per condition was performed with Image J 1.44 m soft-
ware (National Institutes of Health, Bethesda, MD).
Levels of cGMP, a marker of NO bioavailability, were analyzed in liver homogenates using an enzyme immu-
noassay (Cayman Chemical Co., Ann Arbor, MI) as previously described4.
Nitrotyrosine fluorohistochemistry. Quantitative tyrosine nitration detection was performed as pre-
viously described45,22. Briefly, slides were deparaffinized, hydrated, incubated with aqueous sodium dithionite 
solution (10 mM) for 10 min, washed with distilled water and then incubated overnight at 4 °C with an equimolar 
solution of AlCl3 and salicylaldehyde (200 mM). Afterwards, the aqueous solution was removed and sections were 
mounted in Fluoromount G medium (Southern Biotech, Birmingham, AL). Negative and positive internal con-
trols were included. Fluorescence images were obtained with a fluorescence microscope and quantitative analysis 
of at least six images per sample was performed with Image J 1.44 m software.
www.nature.com/scientificreports/
1 1Scientific RepoRts | 6:22107 | DOI: 10.1038/srep22107
Neutrophil infiltration. For the evaluation of neutrophil infiltration, paraffin embedded slides were stained 
for specific esterase activity using a commercial available kit (Naphthol AS-D Chloroacetate Kit, Sigma-Aldrich) 
following manufacturer’s instructions. Six images per preparation were obtained and positive cells per field were 
counted.
VCAM-1 and CD68 immunofluorochemistry. Liver cryosections of 6 μm thickness were fixed with ace-
tone at − 20 °C for 10 min, incubated with anti-VCAM-1 (1:150; BD Biosciences) 2 h at room temperature and 
incubated with secondary antibody Alexa Fluor 555 (1:300; Life Technologies, Alcobendas, Madrid, Spain) and 
4′ ,6-diamino-2-fenilindol (1;3000; DAPI, Sigma-Aldrich) and mounted in Fluoromount G medium.
For CD68 detection paraffin embedded samples were used. After antigen retrieval procedure, sections were 
incubated with anti-CD68 (1:100; BioRad, El Prat de Llobregat, Barcelona, Spain) 1 h at room temperature and 
incubated with secondary antibody and mounted as described before.
Ten images per sample were obtained with a fluorescence microscope and percentage of positive area (VCAM-1) 
or positive cells per field (CD68) were quantified.
Cell death. Terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) was performed in 
deparaffined liver sections using an In Situ Cell Death Detection Kit (Roche Diagnostics, Sant Cugat del Valles, 
Barcelona, Spain) according to the manufacturer’s instructions.
Statistical Analysis. Statistical analyses were performed with the IBM SPSS Statistics 19 for Windows sta-
tistical package. All results are expressed as mean ± standard error of the mean. Comparisons between groups 
were performed with analysis of variance followed by LSD post-hoc test, or with Student’s t test when adequate. 
Differences were considered significant at p < 0.05.
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